Emergency department management of a myasthenia gravis patient with community-acquired pneumonia: Does initial antibiotic choice lead to cure or crisis?

Journal of Emergency Medicine

Volumn 50, Issue 2, 2016, Pages 281-285

  Van Berkel, Megan A ^a   Twilla, Jennifer D ^a   England, Bryan S ^a  

^a Methodist Healthcare   (United States)

Author keywords

community acquired pneumonia; infection; myasthenia gravis; myasthenic crisis; tigecycline

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AZATHIOPRINE; AZITHROMYCIN; AZTREONAM; CALCIUM CARBONATE; CARVEDILOL; DIGOXIN; DOXYCYCLINE; FUROSEMIDE; LISINOPRIL; MOXIFLOXACIN; OMEPRAZOLE; OXYGEN; PENICILLIN DERIVATIVE; PREDNISONE; PYRIDOSTIGMINE; RIVAROXABAN; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE; QUINOLONE DERIVATIVE;

AGED; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ATELECTASIS; ATRIAL FIBRILLATION; BLOOD PRESSURE MEASUREMENT; BODY TEMPERATURE; BREATHING RATE; CARDIOMEGALY; CASE REPORT; COLON CANCER; COMMUNITY ACQUIRED PNEUMONIA; CONGESTIVE HEART FAILURE; COUGHING; DECREASED APPETITE; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DYSPNEA; EMERGENCY WARD; EXTUBATION; FAMILY HISTORY; FEMALE; HEARING IMPAIRMENT; HEART EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; LENGTH OF STAY; LEUKOCYTE COUNT; MEASLES LIKE RASH; MEDICAL HISTORY; MYASTHENIA GRAVIS; OXYGEN SATURATION; PHYSICAL EXAMINATION; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; SINUS RHYTHM; TACHYPNEA; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VERY ELDERLY; WEAKNESS; ANALOGS AND DERIVATIVES; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; DISEASE COURSE;

AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DISEASE PROGRESSION; FEMALE; FLUOROQUINOLONES; HUMANS; MINOCYCLINE; MYASTHENIA GRAVIS; PNEUMONIA;

EID: 84957848764     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2015.04.019     Document Type: Article

References (32)

1. A. Jani-Acsadi, and R.P. Lisak Myasthenic crisis: guidelines for prevention and treatment J Neurol Sci 261 2007 127 133
2. E.M. Bershad, E.S. Feen, and J.I. Suarex Myasthenia gravis crisis South Med J 101 2008 63 69
3. R.W. Barrons Drug-induced neuromuscular blockade and myasthenia gravis Pharmacotherapy 17 1997 1220 1232
4. J. O'Riordan, M. Javed, C. Doherty, and et al. Worsening of myasthenia gravis on treatment with imipenem/cilastatin J Neurol Neurosurg Psychiatry 57 1994 383
5. A. Chaudhuri, and P.O. Behan Myasthenia crisis Q J Med 102 2009 97 107
6. B. Moore, M. Safani, and J. Keesy Possible exacerbation of myasthenia gravis by ciprofloxacin [letter] Lancet 1 8590 1988 882
7. C.S. Jones, A. Sorbello, and R.M. Boucher Fluoroquinolone-associated myasthenia gravis exacerbation. Evaluation of Postmarketing Reports from the US FDA Adverse Event Reporting System and Literature Review Drug Saf 34 2011 839 847
8. M. Deng, Y.F. Wang, F. Hu, and et al. Effect of different kinds of antibiotics on transmission function at the neuromuscular junction in mice with myasthenia gravis Chin J Clin Rehabil 9 2005 233 235
9. J.P. Sieb Fluoroquinolone antibiotics block neuromuscular transmission Neurology 50 1998 804 807
10. E.T. Wittbrodt Drugs and myasthenia gravis Arch Intern Med 157 1997 399 408
11. J.R. Absher, and J.F. Bale Aggravation of myasthenia gravis by erythromycin J Pediatr 119 1991 155 156
12. E. Pijpers, R.E.N. van Rijswijk, B. Takx-Kohlen, and G. Scbrey A clarithromycin-induced myasthenic syndrome Clin Infect Dis 22 1996 176 178
13. Reuters Aventis urges extreme caution with Ketek in patients with myasthenia gravis [editor's comment] Clin Infect Dis 36 2003 ii
14. X. Perrot, N. Bernard, C. Vial, and et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment Neurology 67 2006 2256 2258
15. F. Van Bambeke, J.M. Harms, Y. Van Laethem, and et al. Ketolides: pharmcolotical provile and rational positioning in the treatment of respiratory tract infections Expert Opin Pharmacother 9 2008 267 283
16. US Food and Drug Administration. Labeling revision. June 29, 2006. Supplemental New Drug Application (NDA 21-144/S-01). Ketek TM (telithromycin) [online]. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2006/021144s011ltr.pdf. Accessed October 27, 2014.
17. R.B. Nieman, H. Edelberg, and S.E. Caffe Telithromycin and myasthenia gravis [letter] Clin Infect Dis 37 2003 1579
18. D.B. Ross The FDA and the case of Ketek N Engl J Med 356 2007 1601 1604
19. Z. Argov, T. Brenner, and O. Abramsky Ampicillin may aggravate clinical and experimental myasthenia gravis Arch Neurol 43 1986 255 256
20. st edn 2008 Myasthenia Gravis Foundation of America St Paul, MN
21. E. Hokkanen Antibiotics in myasthenia gravis [letter] Br Med J 1 5390 1964 1111 1112
22. E. Hokkanen The aggravating effect of some antibiotics on the neuromuscular blockade in myasthenia gravis Acta Neurol Scand 40 1964 346 352
23. M.P. McQuillen, H.E. Cantor, and J.R. O'Rourke Myasthenia syndrome associated with antibiotics Arch Neurol 18 1968 402 415
24. B.V. Maramattom, and E.F.M. Wijdicks Acute neuromuscular weakness in the intensive care unit Crit Care Med 34 2006 2835 2841
25. U.K. Dhand Clinical approach to the weak patient in the intensive care unit Resp Care 51 2006 1024 1041
26. Product Information: TYGACIL(R) intravenous injection, tigecycline intravenous injection 2013 Wyeth Pharmaceuticals, Inc. (per FDA) Philadelphia, PA
27. L.A. Mandell, R.G. Wunderink, A. Anzueto, and et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults Clin Infect Dis 44 Suppl. 2 2007 S27 S72
28. Quality Net. Specifications Manual for National Hospital Inpatient Quality Measures. Version 4.3b. Discharges 01-01-14 (1Q14) through 12-31-14 (4Q14). http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228773564870. Accessed October 28, 2014.
29. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. September 27, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm. Accessed October 27, 2014.
30. P.C. McGoven, M. Wible, A. El-Tahtawy, and et al. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials Int J Antimicrob Agents 41 2013 463 467
31. P.E. Verde, and D. Curcio Imbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysis [letter] Clin Infect Dis 55 2012 471 472
32. P. Montravers, H. Dupont, J. Bedos, and et al. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting Intensive Care Med 40 2014 988 997